SCHEMBL360530

SCHEMBL360530

CCOC(=O)c1c(N2CCOCC2)sc2c1CCCC2=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.67
LMNA P02545 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
HSD17B10 Q99714 5/20 0.48
HPGD P15428 5/20 0.48
KDM4E B2RXH2 5/20 0.48
MAPT P10636 5/20 0.48
GAA P10253 4/20 0.48
TSHR P16473 3/20 0.48
MAPK1 P28482 3/20 0.48
GLA P06280 1/20 0.48
ALOX15 P16050 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
KMT2A Q03164 3/20 0.43
USP2 O75604 1/20 0.42
PKM P14618 1/20 0.42
ALOX12 P18054 1/20 0.42
GRM6 O15303 1/20 0.42
THRB P10828 1/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10330147 0.91 ALDH1A1 (0.69) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL14929964 0.81 ALDH1A1 (0.62) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL3922541 0.79 ALDH1A1 (1.00) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL14076494 0.79 ALDH1A1 (0.65) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL14924761 0.78 ALDH1A1 (0.65) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL3765154 0.76 ALDH1A1 (0.62) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL3091939 0.76 ALDH1A1 (0.65) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL3755397 0.76 PIK3CA (0.47) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL3764678 0.75 MAP2K2 (0.49) ALDH1A1LMNASMN1; SMN2HSD17B10HPGD
SCHEMBL3764986 0.73 PIK3CD (0.49) ALDH1A1LMNASMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116267-A1 Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2013-05-09 US claimed
WO-2012009452-A1 THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) 2012-01-19 WO claimed
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-20130116267-A1 Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2013-05-09 US disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20120184519-A1 Compositions and Methods for Preventing or Treating Influenza Virus Infection THE BABRAHAM INSTITUTE 2012-07-19 US disclosed
WO-2012009452-A1 THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) 2012-01-19 WO disclosed
WO-2012009452-A1 THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) 2012-01-19 WO disclosed
US-20110135655-A1 Role of PI3K p110 delta Signaling in Retroviral Infection and Replication PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; 2011-06-09 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135655-A1 Role of PI3K p110 delta Signaling in Retroviral Infection and Replication PIK3R5, PIK3R4, PIK3R1 ALDH1A1 4805/4885LMNA 4020/4885SMN1; SMN2 4128/4885
US-20120184519-A1 Compositions and Methods for Preventing or Treating Influenza Virus Infection PIK3R5, PIK3C2A, PIK3C2B ALDH1A1 4609/4885LMNA 2927/4885SMN1; SMN2 4344/4885
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ALDH1A1 3061/4885LMNA 4870/4885SMN1; SMN2 1864/4885
US-20130116267-A1 Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication PIK3R5, PIK3R4, PIK3R3 ALDH1A1 4867/4885LMNA 3891/4885SMN1; SMN2 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.